Triazole derivative with anti-depression effect as well as preparation method and application thereof
By synthesizing and applying new triazole derivatives, it can effectively inhibit the secretion of inflammatory factors in microglia, solve the problem of poor effect of existing antidepressant drugs on neuroinflammation treatment, and provide a new antidepressant treatment plan .
Patent Information
- Application Number
- CN202411118155.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-08-08
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing antidepressants are difficult to effectively inhibit neuroinflammation, resulting in limited therapeutic effects on depression, especially the secretion and activity of inflammatory factors such as IL-1β, IL-6, TNF-α released by microglia are difficult to produce. Effectively inhibit.
By synthesizing a new triazole derivative with a structure of 2-[3-cyano-4-(2-isobutoxy)-phenyl]-4-methylthiazole-5-carboxylic acid, and by The click reaction reacts with azide compounds to obtain compounds with good anti-inflammatory activity, which are used to inhibit the secretion of inflammatory factors in microglia.
This compound shows good anti-inflammatory activity, can effectively inhibit the secretion of inflammatory factors such as IL-6, and has potential anti-depressant treatment effects, providing a new direction for drug development.
Smart Images

Figure CN118994140A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug synthesis, and specifically relates to a preparation method and application of a triazole derivative with antidepressant effect. Background Art
[0002] Neuroinflammation is an important pathological sign of depression. In the brains of patients with depression, Aβ protein misfolds and aggregates, interacts with pattern receptors on the surface of microglia, activates microglia, releases a large number of inflammatory factors, and causes neuroinflammation. Neuroinflammation can aggravate neuronal damage and lead to chronic neuroinflammation. Some external or internal environmental factors can also cause persistent neuroinflammation and increase the risk of the occurrence and development of depression. For example, infection, obesity, and brain trauma can excessively release and accumulate inflammatory factors, causing chronic neuroinflammation, thereby increasing the likelihood of depression. The occurrence of specific inflammatory reactions in brain tissue is a key step in the onset of depression. In addition to phagocytosis, activated microglia also release a variety of inflammatory factors, such as IL-1, IL-6, TNF-α, TGF-β, glutamate, iNOS, ROS, etc. Among them, IL-1β can activate astrocytes and release α1-activated protease, leading to Aβ fibrosis. At the same time, IL-1β can activate the NK-κB pathway, promote microglia to secrete proinflammatory factors, and form a vicious cycle. In addition, IL-1β can upregulate the expression of APP and promote the production of complement protein C3 and carrier protein E. After iNOS is activated, it releases a large amount of NO, causing damage to neurons. The production of ROS exacerbates the toxicity of Aβ and activates the NK-κB pathway, accelerating cell apoptosis. In the development of depression, the continuous activation of microglia and the inflammatory factors and neurotoxic substances they release continue to interact, ultimately leading to the continued development of neurodegenerative lesions.
[0003] 2-[3-Cyano-4-(2-isobutoxy)-phenyl]-4-methylthiazole-5-carboxylic acid is a new oral anti-hyperuricemia drug. Its therapeutic effect is achieved by promoting uric acid excretion and thus lowering serum uric acid. Compared with other drugs in the treatment of gout, it has the advantages of being potent, highly selective, having fewer side effects, and being safer. It has gradually replaced allopurinol and benzbromarone and has become the preferred drug for the current clinical treatment of gout and hyperuricemia.
[0004] N-substituted-1,2,3-triazole is an important class of nitrogen-containing heterocyclic compounds, which plays an important role in the fields of medicine, synthetic chemistry and materials. Among them, some 1,2,3-triazole derivatives have anti-inflammatory activity and can be used as potential drugs for the treatment of inflammation-related diseases. New 1,2,3-triazole derivatives can inhibit the secretion or activity of some inflammatory factors, thereby exerting anti-inflammatory effects. Studies have shown that some N-aryl-substituted-1,2,3-triazoles can inhibit the secretion of IL-6 inflammatory factors. However, when microglia are stimulated by inflammation, they release a large number of inflammatory factors, such as IL-6, IL-1β, TNF-α, etc., leading to neuronal damage and apoptosis. Our team cooperated with Jinan Aisi Pharmaceutical Technology Co., Ltd. Jinan Aisi Pharmaceutical Technology Co., Ltd. is responsible for the synthesis of compounds, and our team is responsible for activity testing. We hope that the synthesized new 1,2,3-triazole derivatives may have potential anti-microglial inflammation effects. Summary of the invention
[0005] In view of the above problems, the purpose of the present invention is to provide a preparation method and application of triazole derivatives with antidepressant effect. The triazole derivatives prepared by the present invention have novel structures and good anti-inflammatory activity, and play an important role in the research and development of antidepressant drugs.
[0006] In order to achieve the above object, the specific scheme adopted by the present invention is:
[0007] In the first aspect, the present invention provides a triazole derivative having antidepressant activity, the structure of which is: Among them, R 1 , R 2 , R 3 , R 4 and R 5 It is one or more of H, halogen, trifluoromethyl, ethyl, phenyl, hydroxyl, cyano, nitro, aromatic ring, etc.
[0008] In a second aspect, the present invention provides a method for preparing the triazole derivative: 2-(3-nitrile-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide, azide compounds, sodium L-ascorbate and anhydrous CuSO4 are added to a round-bottom flask equipped with a stirrer, and then a mixed solvent of water, tert-butyl alcohol and THF in a volume ratio of 1:1:1 is added to the flask, and stirred at room temperature to dissolve all of them; the room temperature is maintained and stirred overnight for 2 hours; after the reaction is completed by TLC detection, DCM is extracted and the lower organic phase is collected; then saturated brine is used for back extraction, the lower organic phase is collected, anhydrous sodium sulfate is added thereto, and the mixture is stirred thoroughly and allowed to stand 30min, then filter to remove anhydrous sodium sulfate; distill under reduced pressure at 35°C to obtain a crude product, and then separate and purify the obtained crude product by column chromatography to obtain a white solid, which is a triazole derivative; the azide compound is any one of 2-nitrile benzyl azide, 4-bromobenzyl azide, 2-chloro-5-fluorobenzyl azide, 3-fluorobenzyl azide, 2-bromobenzyl azide, zidovudine, 2-chlorophenyl azide, 2-fluorophenyl azide, 3-chlorophenyl azide, 4-chlorophenyl azide, 4-fluorophenyl azide, 2-trifluoromethylbenzyl azide, 2-trifluoromethoxyphenyl azide, 3-trifluoromethylbenzyl azide, 2-chloro-6-fluorobenzyl azide, 4-trifluoromethylbenzyl azide and 4-fluorobenzyl azide.
[0009] As a further optimization of the above technical solution, the present invention also provides a preparation method of individual raw materials used in the above preparation process.
[0010] In a third aspect, the present invention provides the use of the above triazole derivatives in the preparation of antidepressant drugs.
[0011] Beneficial effects: The present invention is based on the structure of 2-[3-cyano-4-(2-isobutyloxy)-phenyl]-4-methylthiazole-5-carboxylic acid, introduces a terminal alkyne into its structure, and then reacts with azide compounds through a click reaction to obtain more than ten compounds with novel structures. Experiments have shown that the obtained compounds have good anti-inflammatory activity and are expected to be used in the treatment of depression, which has a strong guiding role in the research and development of anti-depression drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 This is the H NMR spectrum of compound 8.16.
[0013] Figure 2 This is a schematic diagram of molecular docking of compound 8.16. DETAILED DESCRIPTION
[0014] The above contents of the present invention are further described in detail below through examples, but this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples, and all technologies implemented based on the above contents of the present invention belong to the scope of the present invention.
[0015] In the following examples, unless otherwise specified, the reagents used are conventional commercially available reagents, and the operating methods adopted are conventional technical means.
[0016] Example 1
[0017] To a reaction flask equipped with a thermometer, a stirrer and a reflux condenser, 4-hydroxybenzaldehyde (5.00 g), hydroxylamine hydrochloride (3.41 g), sodium formate dihydrate (5.11 g) and 50 mL of anhydrous formic acid were added in sequence, stirred evenly at room temperature, heated to reflux reaction for 60 min, then cooled to 45 ° C, and most of the solvent was removed by vacuum distillation. 50 mL of ethanol was added to the remaining solution, stirred at room temperature, a large amount of solid precipitated, filtered, and the filtrate was evaporated under reduced pressure at 45 ° C, and then 50 mL of water was added and heated for recrystallization. After filtering, the mixture was washed with water and dried in vacuo at 45 ° C to obtain 4.31 g of 4-hydroxybenzonitrile.
[0018] Example 2
[0019] To a three-necked flask, 4-hydroxybenzonitrile (4.12 g), 40 mL of ethanol, and 20 mL of hydrochloric acid were added in sequence. After stirring and dissolving, thioacetamide (3.02 g) was added. 30 mL of glacial acetic acid was added dropwise at room temperature. After the addition was complete, the temperature was raised to reflux and the reaction was carried out for a period of time. After the reaction was completed as detected by thin layer chromatography (TLC), ethyl 2-chloroacetoacetate (6.08 g) was added dropwise under reflux. After the addition was complete, the reflux state was maintained with stirring for 4 hours, and then cooled to room temperature. The pH of the solution was adjusted to neutral with aqueous ammonia, the solution was separated into layers, the lower supernatant was taken and crystallized at 0-5°C, filtered, and dried to obtain 6.86 g of ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate.
[0020] Example 3
[0021] To a three-necked flask, 1.2 g of 4-hydroxybenzonitrile, 20 mL of ethanol, and 20 mL of hydrochloric acid were added in sequence, and 0.9 g of thioacetamide was added after stirring and dissolving. 15 mL of glacial acetic acid was added dropwise at room temperature. After the addition was complete, the temperature was raised to reflux for reaction for a period of time. After the reaction was completed by thin layer chromatography (TLC), 2 g of 2-chloro-N-(2-methylbut-3-yn-2-yl)-3-oxobutanamide was added dropwise under reflux. After the addition was complete, the reflux state was maintained and stirred for 4 hours, and then cooled to room temperature. The pH of the solution was adjusted to neutral with aqueous ammonia, the solution was separated into layers, the lower clear liquid was taken and crystallized at 0-5°C, filtered, and dried to obtain 2-(4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide.
[0022] Example 4
[0023] Add 27g of polyphosphoric acid to a reaction kettle with a temperature regulating device, slowly add 3g of water dropwise while stirring, continue stirring for 10min after the addition, and control the temperature of the reaction system at 40°C; add 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester 26.3g, stir for 10min, control the temperature of the reaction liquid, slowly add 15.4g of urotropine to the reaction system, keep the temperature at 40-50°C during the addition process, stir for 20min after the addition, slowly heat the reaction liquid, and The reaction solution temperature was raised to 90-95°C, and the reaction was kept warm for about 2 hours. After the reaction was completed, the temperature was lowered to below 40°C, and 48 g of water was slowly added dropwise. After the addition, it was stirred at room temperature for 2 hours, and then the temperature was lowered to 5°C, stirred and crystallized for 1 hour, and centrifuged. After the filter cake was dried, 70 g of ethanol was added, and then heated until completely dissolved, and then the temperature was lowered to 5°C, stirred and crystallized for 1 hour, and centrifuged. The filter cake was rinsed once with cold ethanol and dried to obtain 25.7 g of ethyl 2-(3-aldehyde-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate.
[0024] Example 5
[0025] To a three-necked flask, 1.2 g of 4-hydroxybenzonitrile, 15 mL of ethanol, and 15 mL of hydrochloric acid were added in sequence. After stirring and dissolving, 0.9 g of thioacetamide was added. 10 mL of glacial acetic acid was added dropwise at room temperature. After the addition was complete, the temperature was raised to reflux for reaction for a period of time. After the reaction was completed by thin layer chromatography (TLC), 1.64 g of ethyl 2-chloroacetoacetate was added dropwise under reflux. After the addition was complete, the reflux state was maintained and stirred for 4 hours, and then cooled to room temperature. The pH of the solution was adjusted to neutral with ammonia water. The solution was separated into layers, and the lower clear liquid was taken for crystallization at 0-5°C, filtered, and dried. 30 mL of tetrahydrofuran was added, and magnesium chloride (1.4 g) was added. , zinc cyanide (0.3g), triethylamine (1.5g) and paraformaldehyde (1.5g), slowly heated to 65℃, stirred and reacted for 3h, filtered the reaction solution, slowly added 2mL of acetic acid to the reaction system, continued to stir and react for 2h, filtered the reaction system after the reaction, and then cooled the filtrate to 0℃, stirred and crystallized for 2h, filtered, dried the filter cake after suction, added 30g of ethanol, and then heated until completely dissolved, then cooled to 5℃, stirred and crystallized for 1h, centrifuged, rinsed the filter cake once with cold ethanol, and dried to obtain 2.51g of primary 2-(3-aldehyde-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester.
[0026] Example 6
[0027] Add 27 g of polyphosphoric acid to a reaction kettle with a temperature regulating device, slowly add 3 g of water under stirring, continue stirring for 10 min after the addition, and control the temperature of the reaction system at 50°C; add 30 g of 2-(4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide, stir for 10 min, control the temperature of the reaction liquid, slowly add 17 g of urotropine to the reaction system, keep the temperature at 50°C during the addition process, stir for 20 min after the addition, slowly heat the reaction liquid, and raise the temperature of the reaction liquid to 90 ~95℃, keep warm for about 2~3h. After the reaction is completed, cool to below 40℃, slowly add 60g of water, stir at room temperature for 2h after the addition, then cool to 5±5℃, stir and crystallize for 2h, centrifuge, add 120g of ethanol after drying the filter cake, and then heat until completely dissolved, then cool to 5±5℃, stir and crystallize for 1h, centrifuge, rinse the filter cake once with cold ethanol, and spin dry to obtain 28.8g of 2-(3-aldehyde-4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide.
[0028] Example 7
[0029] In a high-pressure reactor, 1.2 g of 4-hydroxybenzonitrile and 1.3 g of triethylamine were dissolved in 30 mL of a solution in dry pyridine, hydrogen sulfide was introduced into the reactor to make the pressure in the reactor reach 0.05 MPa, the reaction pressure was kept constant and stirred in a sealed reactor at room temperature for 6 h, the reaction solvent was evaporated in vacuo, and then the obtained solid was washed several times with petroleum ether, the solid and 2-chloro-N-(2-methylbut-3-yn-2-yl)-3-oxobutanamide 2.4 g were heated to reflux in 20 mL of ethanol, and after 20 h, the reaction solution was vacuum concentrated, 3 mL of concentrated hydrochloric acid was added to the concentrate and heated to reflux with stirring for 2 h, after cooling, the reaction mixture was filtered to remove insoluble matter, and the acidic filtrate was neutralized with hydrated sodium bicarbonate solution, the precipitate was collected by filtration, and purified by recrystallization from toluene-petroleum ether, and then triethylamine was added. 100 mL of fluoroacetic acid was stirred at 40-50 ° C for 10 min, the temperature of the reaction liquid was controlled, and urotropine (5.2 g) was slowly added to the reaction system, and the temperature was maintained at 40-50 ° C during the addition process. After the addition, it was stirred for 20 min, and the reaction liquid was slowly heated to reflux. The reaction was kept warm for about 40 hours. After the reaction was completed, the reaction liquid was concentrated in vacuo, about 60 mL of trifluoroacetic acid was evaporated, and then the temperature was lowered to below 40 ° C, and 20 g of water was slowly added dropwise. After the addition, it was stirred at room temperature for 2 h, and then cooled to 0 ° C, stirred and crystallized for 2 hours, centrifuged, and after the filter cake was dried, 50 g of ethanol was added, and then heated until completely dissolved, and then cooled to 05 ° C, stirred and crystallized for 1 h, centrifuged and dried to obtain 2-(3-aldehyde-4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide.
[0030] Example 8
[0031] To a three-necked flask, 1.2 g of 4-hydroxybenzonitrile, 15 mL of ethanol, and 15 mL of hydrochloric acid were added in sequence. After stirring and dissolving, 0.9 g of thioacetamide was added. 10 mL of glacial acetic acid was added dropwise at room temperature. After the addition was complete, the temperature was raised to reflux for reaction for a period of time. After the reaction was completed by thin layer chromatography (TLC), 2.4 g of 2-chloro-N-(2-methylbut-3-yn-2-yl)-3-oxobutyramide was added dropwise under reflux. After the addition was complete, the reflux state was maintained and stirred for 4 hours, then cooled to room temperature, the pH of the solution was adjusted to neutral with ammonia water, the solution was separated into layers, the lower clear liquid was taken and crystallized at 0-5°C, filtered, 30 mL of tetrahydrofuran was added after drying, and magnesium chloride was added (1.4g), zinc cyanide (0.3g), triethylamine (1.5g) and paraformaldehyde (1.5g), slowly heated to 65°C, stirred for reaction for 5h, cooled after the reaction, added 5% hydrochloric acid solution to the reaction system, adjusted the pH of the reaction system to about 3, then cooled to 0°C, stirred for crystallization for 2 hours, centrifuged, added 30g of ethanol after the filter cake was dried, and then heated until completely dissolved, then cooled to 5±5°C, stirred for crystallization for 1h, centrifuged, rinsed the filter cake once with cold ethanol, and dried to obtain 2-(3-aldehyde-4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide.
[0032] Example 9
[0033] In a reaction kettle with a temperature regulating device, 29 g of ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate, 20 g of isobutyl bromide and 20 g of anhydrous potassium carbonate were added to 500 g of N,N-dimethylformamide, stirred evenly and heated to 90°C. The reaction was kept warm for 5 hours, and sampling was performed. HPLC was used for control. When the content of ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate was less than 0.5%, the reaction was completed. If the reaction was not complete, sampling was performed every 1 hour. When the reaction was complete, After completion, the temperature was slowly lowered to 20-30°C, and 150 g of drinking water was slowly added. During the stirring process, the reaction solution was cooled to 5-10°C, stirred and crystallized for 1 hour, centrifuged, and the filter cake was dried and transferred to another clean reactor containing 130 g of isopropanol, slurried at room temperature for 1 hour, and then cooled to 5-10°C, stirred and crystallized for 1 hour, centrifuged, and the filter cake was rinsed with isopropanol (0.5 times the amount), filtered and dried to obtain 31.4 g of ethyl 2-(3-aldehyde-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate.
[0034] Example 10
[0035] In a reaction kettle with a temperature regulating device, 32.8 g of 2-(3-formyl-4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide, 20 g of isobutyl bromide and 20 g of anhydrous potassium carbonate were added to 500 g of N,N-dimethylformamide, stirred evenly and heated to 90°C. The reaction was kept warm for 5 hours, and sampling was performed for detection. HPLC was used for control. When the content of ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate was less than 0.5%, the reaction was completed. If the reaction was not complete, sampling was performed every 1 hour. The reaction was continued for 5 hours. After completion, the temperature was slowly lowered to 20-30°C, and 150 g of drinking water was slowly added. During the stirring process, the reaction solution was cooled to 5-10°C, stirred and crystallized for 1 hour, centrifuged, and the filter cake was dried and transferred to another clean reactor containing 150 g of isopropanol, slurried at room temperature for 1 hour, and then cooled to 5-10°C, stirred and crystallized for 1 hour, centrifuged, and the filter cake was rinsed with isopropanol (0.5 times the amount), filtered and dried to obtain 33.2 g of 2-(3-aldehyde-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide.
[0036] Embodiment 11
[0037] In a reaction kettle with a temperature regulating device, 300 g of anhydrous formic acid was added, and then 35 g of ethyl 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate, 7.7 g of hydroxylamine hydrochloride and 12.5 g of sodium formate dihydrate were added in sequence. The reaction was heated under reflux for 2 h, and sampling was performed for detection. HPLC was used for control. When the content of ethyl 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate was less than 0.5%, the reaction was completed (the color of the reaction liquid changed from light yellow to yellow during the reaction). If the reaction was not complete, sampling was performed every 0.5 h. During the heating process, the reaction liquid would solidify rapidly, and the stirring speed needed to be increased to make it evenly stirred. After the reaction was completed, the reaction liquid was cooled. When the mixture is cooled to 20-30°C, the reaction solution will solidify. The stirring speed needs to be increased to make it evenly stirred, and then drinking water is slowly added. After the addition, the reaction solution is cooled to 10-20°C, stirred and crystallized for 1 hour, and centrifuged. The filter cake is soaked and washed once with drinking water (2 times the amount), rinsed with drinking water (1 times the amount) once, and rinsed with ethanol water (1:1, v:v, 1 times the amount) once. Finally, the pH of the washing solution is close to neutral. After drying, 140 kg of ethanol is added, and the mixture is heated to reflux and pulped for 1 hour, then cooled to 5-10°C, stirred and crystallized for 1 hour, and the filter cake is rinsed with ethanol (0.5 times the amount) after centrifugation. After drying, 32.2 g of ethyl 2-(3-nitrile-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate is obtained.
[0038] Example 12
[0039] In a reaction kettle with a temperature regulating device, add 300 g of ethanol, then add 35 g of ethyl 2-(3-nitrile-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate, heat to 50°C, slowly add 20 g of 20% sodium hydroxide (in the process of adding sodium hydroxide, the solid gradually dissolves), keep the temperature at 50°C during the addition process, and continue to stir the reaction for 1 hour after the addition is completed (the reaction liquid gradually becomes clear during the reaction process). Sampling and testing, HPLC control, when 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester is less than 0.1%, the reaction is completed. If the reaction is not complete, sampling is performed every 0.5h. After the reaction is completed, the reaction solution is cooled to below 20°C, 2 mol / L dilute hydrochloric acid is slowly added dropwise to adjust the pH to 2-3, and the temperature of the reaction solution is controlled to be less than 30°C during the acidification process. During this period, a large amount of milky white solid is continuously precipitated. After acidification, it is kept at 10-20°C and stirred for crystallization for 1h, centrifuged, and the filter cake is soaked and washed once with drinking water (2 times the amount), rinsed once, and finally the pH of the washing solution is close to neutral, ethanol (90%, 0.5 times the amount) is rinsed, and dried to obtain 30.4g of 2-(3-nitrile-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid.
[0040] Example 13
[0041] Into a 500 mL clean round-bottom flask equipped with a stirring bar, 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid (0.02 mol), 2-methyl-2-amino-butyne (0.03 mol), HATU (0.03 mol) and DIPEA (0.06 mol) were added in sequence. Then, 300 mL of N,N-dimethylformamide was added to the system and stirred at room temperature for 1 h. 200 mL of water was added to the reaction system. A large amount of solid was precipitated during the stirring process. The solid was filtered and dried to obtain 7.3 g of 2-(3-nitrile-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide.
[0042] Embodiment 14
[0043] In a reaction kettle with a temperature regulating device, add 175 g of anhydrous formic acid, then add 35 g (0.1 mol) of 2-(3-formyl-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide, 7.7 g (0.11 mol) of hydroxylamine hydrochloride and 12.5 g (0.12 mol) of sodium formate dihydrate in sequence, heat and reflux to react for 2 h. After the reaction of the raw materials is completed under TLC monitoring, the reaction solution is cooled to 20-30 ° C, the stirring speed is increased to make it stir evenly, and then 100 g of drinking water is slowly added. After the addition is complete, react. The reaction solution was cooled to 10-20°C, stirred for crystallization for 1h, centrifuged, the filter cake was soaked and washed once with 70g of drinking water, then rinsed once with 35g of drinking water, and rinsed once with 35g of 50% ethanol solution. The pH of the washing solution was close to neutral. After drying, 140g of ethanol was added, heated to reflux and slurried for 1h, then cooled to 5-10°C, stirred for crystallization for 1h, filtered, and the filter cake was rinsed with ethanol (0.5 times the amount), and dried to obtain 29.1g of the primary product 2-(3-nitrile-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide.
[0044] Embodiment 15
[0045] Take 2-(3-nitrile-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide (1mmol), 2-nitrile benzyl azide (1.2mmol), L-sodium ascorbate (2mmol) and anhydrous CuSO4 (1mmol) and add them to a 100mL round-bottom flask equipped with a stirrer, then add 50mL of a mixed solvent of water: tert-butyl alcohol: THF = 1:1:1 (v / v / v) to the flask, stir at room temperature for 10min to dissolve it completely. Keep room temperature, stir overnight to react, and after the reaction is completed by TLC detection, extract with DCM 3 times, and collect the lower organic phase. Then extract with saturated brine 3 times, collect the lower organic phase, add anhydrous sodium sulfate to it, stir well and let stand for 30min, then filter to remove anhydrous sodium sulfate. Organic solvents such as DCM were removed by distillation under reduced pressure at 35°C to obtain a crude product, which was then separated and purified by column chromatography to obtain solid 8.1; 1HNMR(400MHz,DMSO-d6):8.36(s,1H),8.25(d,J=4.0Hz,1H),8.17(dd,J1=4.0 Hz,J2=4.0Hz,1H),8.10(s,1H),7.93(d,J=4.0Hz,1H),7.73(t,J=8.0Hz,1H), 7.57(t,J=8.0Hz,1H),7.38(d,J=8.0Hz,1H),7.32(d,J=8.0Hz,1H),5.80(s,2 H), 4.01 (d, J = 8.0Hz, 2H), 2.56 (s, 3H), 1.70 (s, 6H), 1.03 (s, 3H), 1.02 (s, 3H).
[0046] Example 16
[0047] The synthesis method of compound 8.2 is similar to that of compound 8.1, except that 4-bromobenzyl azide is used to replace 2-nitrilebenzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.2; 1 H NMR (400MHz, DMSO-d6): 8.32 (s, 1H), 8.25 (d, J = 4.0Hz, 1H), 8.17 (dd, J1 = 4.0Hz, J2 = 4.0Hz, 1H), 8.04 (s, 1H), 7.59 (d, J = 8.0Hz, 2H), 7 .38(d,J=8.0Hz,1H),7.28(d,J=8.0Hz,2H),5.56(s,2H),4.01(d,J=8.0Hz,2H),2.56(s,3H),1.69(s,6H),1.03(s,3H),1.02(s,3H).
[0048] Embodiment 17
[0049] The synthesis method of compound 8.3 is similar to that of compound 8.1, except that 2-chloro-5-fluorobenzyl azide is used to replace 2-nitrilebenzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.3; 1H NMR(400MHz, DMSO-d6):8.37(s,1H),8.25(d,J=4.0Hz,1H),8.18(dd,J1=4.0H z,J2=4.0Hz,1H),8.08(s,1H),7.59(dd,J1=4.0Hz,J2=4.0Hz,1H),7.38(d,J= 8.0Hz,1H),7.31-7.26(m,1H),6.94(dd,J1=4.0Hz,J2=4.0Hz,1H),5.68(s,2H ), 4.01 (d, J = 8.0Hz, 2H), 2.55 (s, 3H), 1.71 (s, 6H), 1.03 (s, 3H), 1.02 (s, 3H).
[0050] Embodiment 18
[0051] The synthesis method of compound 8.4 is similar to that of compound 8.1, except that 3-fluorobenzyl azide is used to replace 2-nitrilebenzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.4; 1 H NMR (400MHz, DMSO-d6): 8.34 (s, 1H), 8.25 (d, J = 4.0Hz, 1H), 8.18 (dd, J1 = 4.0Hz, J2 = 4.0Hz, 1H), 8.08 (s, 1H), 7.46-7. 37(m,2H),7.20-7.12(m,3H),5.61(s,2H),4.01(d,J=8.0Hz,2H),2.56(s,3H),1.70(s,6H),1.03(s,3H),1.02(s,3H).
[0052] Embodiment 19
[0053] The synthesis method of compound 8.5 is similar to that of compound 8.1, except that 2-bromobenzyl azide is used to replace 2-nitrilebenzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.5; 1 H NMR (400MHz, DMSO-d6): 8.38 (s, 1H), 8.25 (d, J = 4.0Hz, 1H), 8.18 (dd, J1 = 4.0Hz, J2 = 4.0Hz, 1H), 8.03 (s, 1H), 7.70 (d, J = 8.0Hz, 1H), 7.42-7. 29(m,3H),7.06(d,J=8.0Hz,1H),5.66(s,2H),4.01(d,J=4.0Hz,2H),2 .56(s,3H),2.15-2.05(m,1H),1.70(s,6H),1.03(s,3H),1.02(s,3H).
[0054] Embodiment 20
[0055] The synthesis method of compound 8.6 is similar to that of compound 8.1, except that zidovudine is used to replace 2-nitrile benzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.6; 1 H NMR(400MHz,DMSO-d6):11.34(s,1H),8.32(s,1H),8.26(s,1H),8.21(d,J=12.0 Hz,2H),7.84(s,1H),7.40(d,J=8.0Hz,1H),6.45(t,J=8.0Hz,1H),5.30-5.20(m ,2H),4.23(d,J=8.0Hz,1H),4.02(d,J=4.0Hz,2H),3.74-3.64(m,3H),2.61(s,3 H),2.41-2.15(m,2H),1.84-1.81(m,5H),1.74(s,3H),1.03(s,3H),1.02(s,3H).
[0056] Embodiment 21
[0057] The synthesis method of compound 8.7 is similar to that of compound 8.1, except that 2-chlorophenyl azide is used to replace 2-nitrile benzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.7.
[0058] Embodiment 22
[0059] The synthesis method of compound 8.8 is similar to that of compound 8.1, except that 2-fluorophenyl azide is used to replace 2-nitrile benzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.8.
[0060] Embodiment 23
[0061] The synthesis method of compound 8.9 is similar to that of compound 8.1, except that 3-chlorophenyl azide is used to replace 2-nitrile benzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.9.
[0062] Embodiment 24
[0063] The synthesis method of compound 8.10 is similar to that of compound 8.1, except that 4-chlorophenyl azide is used to replace 2-nitrile benzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.10; 1H NMR (400MHz, DMSO-d6): 8.75(s,1H),8.41(s,1H),8.25(s,1H),8.20(d,J=8.0Hz,1H),8.00(d,J=8.0Hz,2H),7.69( d,J=8.0Hz,2H),7.40(d,J=12.0Hz,1H),4.03(d,J=4.0Hz,2H),2.61(s,3H),1.79(m,6H),1.05(s,3H),1.04(s,3H).
[0064] Embodiment 25
[0065] The synthesis method of compound 8.11 is similar to that of compound 8.1, except that 4-fluorophenyl azide is used to replace 2-nitrile benzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.11; 1 H NMR(400MHz, DMSO-d6):8.70(s,1H),8.39(s,1H),8.25-8.18(m,2H),8.01-7.97(m,2H),7.47(t,J=8.0H z,2H),7.39(d,J=8.0Hz,1H),4.03(d,J=4.0Hz,2H),2.61(s,3H),1.79(m,6H),1.05(s,3H),1.03(s,3H).
[0066] Embodiment 26
[0067] The synthesis method of compound 8.12 is similar to that of compound 8.1, except that 2-trifluoromethylbenzyl azide is used to replace 2-nitrilebenzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 7.12; 1 H NMR(400MHz, DMSO-d6):8.32(s,1H),8.25(d,J=4.0Hz,1H),8.20-8.17(m,1H), 8.05(s,1H),8.82(d,J=8.0Hz,1H),7.82(d,J=8.0Hz,1H),7.68(t,J=8.0Hz,1H ),7.59(t,J=4.0Hz,1H),7.39(d,J=8.0Hz,1H),7.10(d,J=8.0Hz,1H),5.79(s, 2H), 4.02 (d, J = 8.0Hz, 2H), 2.57 (s, 3H), 1.79 (m, 6H), 1.05 (s, 3H), 1.03 (s, 3H).
[0068] Embodiment 27
[0069] The synthesis method of compound 8.13 is similar to that of compound 8.1, except that 2-trifluoromethoxyphenyl azide is used to replace 2-nitrilebenzyl azide. The crude product is separated and purified by column chromatography to obtain solid 7.13.
[0070] Embodiment 28
[0071] The synthesis method of compound 8.14 is similar to that of compound 8.1, except that 3-trifluoromethylbenzyl azide is used to replace 2-nitrilebenzyl azide. The crude product is separated and purified by column chromatography to obtain solid 7.14.
[0072] Embodiment 29
[0073] The synthesis method of compound 8.15 is similar to that of compound 8.1, except that 2-chloro-6-fluorobenzyl azide is used to replace 2-nitrilebenzyl azide. The crude product is separated and purified by column chromatography to obtain solid 7.15.
[0074] Embodiment 30
[0075] The synthesis method of compound 8.16 is similar to that of compound 8.1, except that 4-fluorobenzyl azide is used to replace 2-nitrilebenzyl azide, and the crude product is separated and purified by column chromatography to obtain solid 8.16; 1 H NMR (400MHz, DMSO-d6): 8.34 (s, 1H), 8.25 (d, J = 4.0Hz, 2H), 8.19 (dd, J1 = 4.0Hz, J2 = 4.0Hz, 1H), 8.04 (s, 1H), 7.41-7.37 (m, 3H) ,7.24-7.20(m,2H),5.56(s,2H),4.01(d,J=4.0Hz,2H),2.56(s,3H),2.13-2.06(m,1H),1.69(m,6H),1.03(s,3H),1.02(s,3H).
[0076] H NMR spectrum Figure 1 As shown, molecular docking Figure 2 shown.
[0077] Embodiment 31
[0078] The synthesis method of compound 8.17 is similar to that of compound 8.1, except that 4-trifluoromethylbenzyl azide is used to replace 2-nitrilebenzyl azide, and the crude product is separated and purified by column chromatography to obtain white solid 8.17; 1H NMR (400MHz, DMSO-d6): 8.36 (s, 1H), 8.25 (d, J = 4.0Hz, 2H), 8.19 (dd, J1 = 4.0Hz, J2 = 4.0Hz, 1H), 8.09 (s, 1H), 7.76 (d, J = 8.0Hz, 2H), 7.50 (d, J = 8.0Hz,2H),7.38(d,J=8.0Hz,1H),5.70(s,2H),4.01(d,J=4.0Hz,2H), 2.55(s,3H),2.13-2.06(m,1H),1.70(m,6H),1.03(s,3H),1.02(s,3H).
[0079] Embodiment 32
[0080] Lipopolysaccharide (LPS)-induced BV2 cell inflammation model: BV2 cells were cultured at 2×10 4 Each well was inoculated on a 96-well culture plate and cultured in a 37°C constant temperature incubator containing 5% CO2. After 24 hours of culture, the corresponding concentration of the test compound was added to the drug group for incubation for 2 hours, and then LPS with a final concentration of 100ng / ml was added to the drug group and the LPS model group. After 24 hours of culture in the incubator, the supernatant of each group was reacted with an equal volume of Griess buffer, and the OD value of each group at a wavelength of 540nm was detected by a microplate reader (BioTek). We can very significantly find that most compounds inhibit LPS-induced BV2 cell activity better than resveratrol; at the same time, the IDO1 enzyme activity assay based on Hela cells was used to study the inhibitory activity of compounds with better NO production rate inhibition activity against IDO1. Under 10μM conditions, it was found that some compounds could inhibit the activity of IDO1 by 51.9%. We randomly selected a molecule in the group that was better than the control and docked it with the IDO1 target. It can be significantly observed that the triazole in the compound structure can interact with the key active site heme in IDO1.
[0081] Table 1. Improvement of compounds on LPS-induced BV2 cell inflammation In the NO generation rate detection, the NO generation rate of the LPS model group was set as 100% (n=3). The data in the table are expressed as mean±SEM. * P<0.05, ** P<0.01 compared with the LPS group. Embodiment 34
[0082] Cell viability test: BV2 cells were cultured at 2×10 4 Each well was inoculated in a 96-well culture plate and cultured in a 37°C constant temperature incubator containing 5% CO2. After 24 hours of culture, the corresponding concentration of the test compound was added to the drug-treated group and incubated for 2 hours, and then LPS was added to the drug-treated group and the LPS model group at a final concentration of 100 ng / mL. Continue to culture for 24 hours, add MTT to each well at a final concentration of 0.5 mg / mL, and perform live cell staining. After incubation in the incubator for 1 hour, discard the culture medium, add 100 μL DMSO to each well, shake on a shaker to fully dissolve it, and use a microplate reader (Biotek) to detect the OD value of each group at a wavelength of 490 nm.
[0083] Table 2. Toxic effects of compounds on BV2 cells
[0084] In the cell survival rate test, the cell survival rate of the LPS model group was set as 100% (n=3). The data in the table are expressed as mean±SEM. * P<0.05, *** P<0.001 versus LPS group.
[0085] The above embodiments describe the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for illustrating the principles of the present invention. Without departing from the scope of the principles of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of protection of the present invention.
Claims
1. Triazole derivatives with antidepressant effects, Features: The structure of the triazole derivative is: Among them, R 1 , R 2 , R 3 , R 4 and R 5 It is one or more of H, halogen, trifluoromethyl, ethyl, phenyl, hydroxyl, cyano, nitro, aromatic ring, etc.
2. The method for preparing the triazole derivative according to claim 1, Features: Take 2-(3-nitrile-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide, azide compounds, sodium L-ascorbate and anhydrous CuSO 4 Add to a round-bottom flask equipped with a stirrer, then add a mixed solvent of water, tert-butyl alcohol and THF to the flask, stir at room temperature to dissolve it completely; keep room temperature and stir overnight to react; after the reaction is completed, extract with DCM, collect the lower organic phase; then back-extract with saturated brine, collect the lower organic phase, add anhydrous sodium sulfate thereto, stir thoroughly, let stand for a period of time, and then filter to remove the anhydrous sodium sulfate; distill under reduced pressure at 35°C to obtain a crude product, and then separate and purify the obtained crude product by column chromatography to obtain a white solid, which is a triazole derivative; The azide compound is any one of 2-nitrile benzyl azide, 4-bromobenzyl azide, 2-chloro-5-fluorobenzyl azide, 3-fluorobenzyl azide, 2-bromobenzyl azide, zidovudine, 2-chlorophenyl azide, 2-fluorophenyl azide, 3-chlorophenyl azide, 4-chlorophenyl azide, 4-fluorophenyl azide, 2-trifluoromethylbenzyl azide, 2-trifluoromethoxyphenyl azide, 3-trifluoromethylbenzyl azide, 2-chloro-6-fluorobenzyl azide, 4-trifluoromethylbenzyl azide and 4-fluorobenzyl azide.
3. The preparation method according to claim 2, Features: The 2-(3-nitrile-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide, azide compounds, sodium L-ascorbate and anhydrous CuSO 4 The molar ratio is 1:1.2:2:
1.
4. The preparation method according to claim 2, Features: The 2-(3-nitrile-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide in the raw materials is prepared by any of the following methods: Method 1: add 2-[3-nitrile-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid, 2-methyl-2-amino-butyne, HATU and DIPEA to a flask in sequence, then add N,N-dimethylformamide, stir at room temperature for 1 hour, add water, solid precipitates during stirring, filter and dry to obtain 2-(3-nitrile-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide; the molar ratio of the 2-[3-nitrile-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid to 2-methyl-2-amino-butyne to HATU and DIPEA is 1:1-1.5:1-1.5:2-3; the reaction formula is as follows: Method 2: Add anhydrous formic acid to the reaction kettle, then add 2-(3-formyl-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide, hydroxylamine hydrochloride and sodium formate dihydrate in sequence, heat and reflux for 2 hours, after the reaction is complete, cool to 20-30°C, stir evenly, slowly add drinking water, after adding, cool the reaction solution and stir to crystallize, centrifuge, soak and wash the filter cake, and rinse until the pH of the washing solution is close to neutral, dry it, add ethanol, and heat and reflux for 2 hours. The mixture is slurried, then cooled and stirred for crystallization, and the filter cake is rinsed with ethanol after suction filtration and dried to obtain 2-(3-nitrile-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide; the molar ratio of the 2-(3-formyl-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide to hydroxylamine hydrochloride and sodium formate dihydrate is 1:1-1.1:1-1.2; the reaction formula is as follows:
5. The preparation method according to claim 4, Features: In method 1, the preparation method of 2-[3-nitrile-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid comprises the following steps: Step 1: Prepare ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate by the following method ① or method ②; Method 1: Add 4-hydroxybenzonitrile, ethanol and hydrochloric acid to a three-necked flask in sequence, stir to dissolve, then add thioacetamide, add glacial acetic acid dropwise at room temperature, raise the temperature to reflux for reaction after complete addition, add ethyl 2-chloroacetoacetate dropwise under reflux, keep stirring under reflux for 4 hours after complete addition, then cool to room temperature, adjust the pH of the solution to neutral with ammonia water, separate the solution into layers, take the clear liquid from the layer, crystallize at 0-5°C, filter and dry to obtain ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate; the molar ratio of the feeding amount of 4-hydroxybenzonitrile to thioacetamide to ethyl 2-chloroacetoacetate is 1:1-1.5:1-1.5; Add polyphosphoric acid to the reaction kettle, slowly add water dropwise while stirring, continue stirring for a while after the addition, and control the temperature of the reaction system at 40°C; add 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester, stir for a while, control the temperature of the reaction solution, slowly add urotropine to the reaction system, keep the temperature at 40-50°C during the addition process, stir for a while after the addition, slowly heat the reaction solution, raise the temperature of the reaction solution to 90-95°C, and keep the temperature for reaction for about 2h. After the reaction is completed, cool to below 40°C, slowly add water dropwise, stir at room temperature for a while after the addition, and then cool to room temperature. Warming to 5°C, stirring for crystallization, centrifuging, drying the filter cake, adding ethanol, and then heating until completely dissolved, then cooling to 5°C, stirring for crystallization for 1 hour, centrifuging, rinsing the filter cake once with cold ethanol, and drying to obtain 2-(3-aldehyde-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester; the molar ratio of the feed amount of 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester to hexamethylenetetramine is 1:1-1.2; the mass ratio of the feed amount of 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester to polyphosphoric acid is 1:1-1.5; Method 2: Add 4-hydroxybenzonitrile, ethanol and hydrochloric acid to a three-necked flask in sequence, stir to dissolve, then add thioacetamide, add glacial acetic acid dropwise at room temperature, raise the temperature to reflux for reaction after complete addition, add ethyl 2-chloroacetoacetate dropwise under reflux, keep stirring under reflux for 4 hours after complete addition, then cool to room temperature, adjust the pH of the solution to neutral with ammonia water, separate the solution into layers, take the clear liquid from the layer and crystallize at 0-5°C, filter, dry, add tetrahydrofuran, then add magnesium chloride, zinc cyanide, triethylamine and polyol Polyoxymethylene, slowly heated to 65°C, stirred for reaction for 3h, filtered the reaction solution, slowly added acetic acid to the reaction system, continued to stir for 2h, filtered the reaction system after the reaction, then cooled the filtrate to 0°C, stirred for crystallization for 2h, filtered, dried the filter cake after suction, added ethanol, heated until completely dissolved, then cooled to 5°C, stirred for crystallization for 1h, centrifuged, rinsed the filter cake with cold ethanol, and dried to obtain 2-(3-aldehyde-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester; the reaction formula is as follows: Step 2: In a reaction kettle, add 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester, isobutane bromide and anhydrous potassium carbonate to N,N-dimethylformamide, stir evenly and heat to 90°C, keep warm and react for 5 hours. After the reaction is completed, slowly cool to 20-30°C, slowly add drinking water, cool the reaction solution and stir to crystallize, centrifuge, dry the filter cake and transfer to another clean reaction kettle filled with isopropanol, beat at room temperature, then cool and stir to crystallize, centrifuge, rinse the filter cake with isopropanol, filter and dry to obtain 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester; the reaction formula is as follows: Step 3, add anhydrous formic acid to the reactor, then add 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester, hydroxylamine hydrochloride and sodium formate dihydrate in sequence, heat and reflux to react for 2h, cool to 20-30°C after the reaction, stir evenly, then slowly add drinking water, cool the reaction solution after adding, stir and crystallize, centrifuge, soak, wash, rinse and dry the filter cake, add ethanol, heat and reflux to pulp, then cool and stir and crystallize, centrifuge, rinse the filter cake with ethanol after centrifugation, and dry to obtain 2-(3-nitrile-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester; the reaction formula is as follows: Step 4, add ethanol to the reaction kettle, then add 2-(3-nitrile-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester, heat to 50°C, slowly add sodium hydroxide dropwise, continue stirring and reacting for 1h after the addition is completed, cool to below 20°C, slowly add dilute hydrochloric acid dropwise, adjust the pH to 2-3, control the temperature of the reaction solution to be less than 30°C during the acidification process, keep warm at 10-20°C after acidification, stir and crystallize, centrifuge, and soak, wash, rinse, and dry the filter cake to obtain 2-(3-nitrile-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid; the reaction formula is as follows:
6. The preparation method according to claim 4, Features: In method 2, the preparation method of 2-(3-formyl-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide comprises the following steps: Step 1: Prepare 2-(3-formyl-4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide by any one of methods 1 to 3: Method 1: Add 4-hydroxybenzonitrile, ethanol and hydrochloric acid to a three-necked flask in sequence, stir to dissolve, then add thioacetamide, add glacial acetic acid dropwise at room temperature, raise the temperature to reflux for reaction after complete addition, add 2-chloro-N-(2-methylbut-3-yn-2-yl)-3-oxobutanamide dropwise under reflux, keep stirring under reflux for a period of time after complete addition, then cool to room temperature, adjust the pH of the solution to neutral with aqueous ammonia, separate the solution into layers, take the clear liquid from the lower layer, crystallize at 0-5°C, filter and dry to obtain 2-(4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide; Add polyphosphoric acid to the reaction kettle, slowly add water dropwise while stirring, continue stirring for 10 minutes after adding, and control the temperature of the reaction system at 50°C; add 2-(4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide, stir for 10 minutes, control the temperature of the reaction solution, add urotropine, stir for a period of time after adding, slowly heat the reaction solution to 90-95°C, and keep the temperature for reaction for 2 hours. After the reaction is completed, cool to below 40°C, slowly add water dropwise, stir at room temperature for 2 hours after adding, then cool and stir to crystallize, centrifuge, add ethanol after drying the filter cake, and then heat until completely dissolved, then cool and stir to crystallize, centrifuge, rinse the filter cake once with cold ethanol, and dry to obtain 2-(3-aldehyde-4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide; Method 2: In a high-pressure reactor, 4-hydroxybenzonitrile and triethylamine are dissolved in a solution of dry pyridine, hydrogen sulfide is introduced to make the pressure in the reactor reach a certain value, the reaction pressure is kept constant and stirred in a sealed reactor at room temperature for 6 hours, the reaction solvent is evaporated in vacuo, and then the obtained solid is washed with petroleum ether for multiple times, the solid and 2-chloro-N-(2-methylbut-3-yn-2-yl)-3-oxobutanamide are heated to reflux in ethanol, and after 20 hours, the reaction solution is vacuum concentrated, a certain amount of concentrated hydrochloric acid is added to the concentrate, heated to reflux and stirred for 2 hours, and after cooling, the reaction mixture is filtered to remove insoluble matter, and the acidic filtrate is neutralized with hydrated sodium bicarbonate solution, the precipitate is collected by filtration, and purified by recrystallization from toluene-petroleum ether, and trifluoroacetic acid is added, and the mixture is heated to 40-60 ℃. The mixture was stirred at 50°C for 10 min, the temperature of the reaction liquid was controlled, and urotropine was slowly added to the reaction system, the temperature was maintained at 40-50°C during the addition process, and the mixture was stirred for 20 min after the addition was completed. The reaction liquid was slowly heated, and the temperature of the reaction liquid was raised to reflux. The reaction was kept warm for about 40 hours. After the reaction was completed, the reaction liquid was vacuum concentrated, trifluoroacetic acid was evaporated, and then the temperature was lowered to below 40°C, and 20 g of water was slowly added dropwise. After the addition was completed, the mixture was stirred at room temperature for a period of time, and then the temperature was lowered and stirred for crystallization, and the mixture was centrifuged. After the filter cake was dried, ethanol was added and then heated until it was completely dissolved, and then the temperature was lowered and stirred for crystallization, and then the mixture was dried after centrifugation to obtain 2-(3-aldehyde-4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide; the reaction pressure value was 0.02-0.06Mpa; Method 3: Add 4-hydroxybenzonitrile, ethanol and hydrochloric acid to a three-necked flask in sequence, stir to dissolve, then add thioacetamide, add glacial acetic acid dropwise at room temperature, raise the temperature to reflux for reaction after complete addition, after the reaction is complete, add 2-chloro-N-(2-methylbut-3-yn-2-yl)-3-oxobutanamide dropwise under reflux, keep stirring at reflux for 4 hours after complete addition, then cool to room temperature, adjust the pH of the solution to neutral with ammonia water, separate the solutions into layers, take the clear liquid from the layer and crystallize at 0-5°C, filter, dry, add tetrahydrofuran, then add magnesium chloride, Zinc cyanide, triethylamine and paraformaldehyde are slowly heated to 65°C, stirred and reacted for 5 hours, cooled after the reaction, and a 5% hydrochloric acid solution is added to the reaction system to adjust the pH of the reaction system to about 3, then cooled and stirred to crystallize, centrifuged, and ethanol is added after the filter cake is dried, and then heated until completely dissolved, cooled and stirred to crystallize, centrifuged, and the filter cake is rinsed once with cold ethanol and dried to obtain 2-(3-aldehyde-4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide; the reaction formula is as follows: Step 2: In a reaction kettle, add 2-(3-formyl-4-hydroxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide, isobutane bromide and anhydrous potassium carbonate to N,N-dimethylformamide, stir evenly and heat to 90°C, keep warm and react for 5 hours. After the reaction is completed, slowly cool to 20-30°C, start to slowly add drinking water, cool the reaction solution and stir to crystallize, centrifuge, dry the filter cake and transfer it to another clean reaction kettle filled with isopropanol, beat at room temperature, then cool and stir to crystallize, centrifuge, rinse the filter cake with isopropanol, filter and dry to obtain 2-(3-formyl-4-isobutoxyphenyl)-4-methyl-N-(2-methylbut-3-yn-2-yl)thiazole-5-carboxamide; the reaction formula is as follows:
7. The preparation method according to claim 5 or 6, Features: The 4-hydroxybenzonitrile is prepared by the following method: 4-hydroxybenzaldehyde, hydroxylamine hydrochloride, sodium formate dihydrate and anhydrous formic acid are added to a reaction bottle in sequence, stirred evenly at room temperature, heated to reflux reaction for a period of time, cooled to 45°C, vacuum distilled, ethanol is added to the remaining solution, stirred at room temperature, filtered, the filtrate is evaporated to dryness under reduced pressure at 45°C, water is added, heated for recrystallization, filtered, washed with water, and vacuum dried at 45°C to obtain 4-hydroxybenzonitrile; the reaction formula is as follows:
8. Use of the triazole derivative according to claim 1 in the preparation of antidepressant drugs.
